Latest articles for News
Conference Coverage
![](https://cdn-uat.mdedge.com/files/s3fs-public/styles/max_width_small/public/images/article_teasers/media_7e3074a_El_Serag_Hashem_B.jpg)
Elevated liver cancer risk after HCV cure may justify surveillance
Sustained virologic response in patients with well controlled hepatic C virus infection does not protect select subgroups of this cohort from...
Conference Coverage
![](https://cdn-uat.mdedge.com/files/s3fs-public/styles/max_width_small/public/images/article_teasers/media_dc311c3_liver4.jpg)
Transplant waiting-list registrations dropped after direct acting–antiviral approval
The number of new waiting-list registrations for liver transplantation among patients with hepatitis C virus declined significantly after the...
Conference Coverage
![](https://cdn-uat.mdedge.com/files/s3fs-public/styles/max_width_small/public/images/article_teasers/media_e8bbb4a_Poordad_Fred_TEXAS.jpg)
Multitargeted drug combination promising when new HCV antivirals fail
Key clinical point: A five-drug antiviral combination appears to be effective for retreatment of patients with hepatitis C virus infection who...
Conference Coverage
![](https://cdn-uat.mdedge.com/files/s3fs-public/styles/max_width_small/public/images/article_teasers/media_040a86f_Hepatitis_C_4.jpg)
Regimen effective in genotype 3 HCV despite advanced cirrhosis
Sustained virologic response in patients with genotype 3 hepatitis C virus (HCV) infection and advanced fibrosis or cirrhosis was achieved in 88%...
Conference Coverage
![](https://cdn-uat.mdedge.com/files/s3fs-public/styles/max_width_small/public/images/article_teasers/media_33a75fd_Magnolia_officinalis.jpg)
Novel botanical drug reduces hepatic fat content
Twelve weeks of treatment with a novel botanical drug extracted from Magnolia officinalis safely and significantly reduced hepatic fat content in...
Conference Coverage
![](https://cdn-uat.mdedge.com/files/s3fs-public/styles/max_width_small/public/images/article_teasers/media_e123b01_Schwimmer_Jeffrey_B_CA.jpg)
Cysteamine bitartrate provides no histologic improvement in children with NAFLD
One year of treatment with delayed-release cysteamine bitartrate was safe and associated with substantial and rapid improvements in liver enzymes...
Conference Coverage
![](https://cdn-uat.mdedge.com/files/s3fs-public/styles/max_width_small/public/images/article_teasers/media_d0a3f30_Hepatitis_C_4.jpg)
ASTRAL-1: High SVR12 with sofosbuvir/velpatasvir combo for HCV
Once-daily treatment with fixed-dose combination sofosbuvir/velpatasvir for 12 weeks was well tolerated and resulted in high sustained virologic...
Conference Coverage
![](https://cdn-uat.mdedge.com/files/s3fs-public/styles/max_width_small/public/images/article_teasers/media_d0a3f30_hepatitis_alcoholic.jpg)
Cellular therapy benefit limited to young alcoholic hepatitis patients
The only patients with alcoholic hepatitis to derive a survival benefit from extracorporeal hepatocellular therapy with C3A hepatoma cells were...
Conference Coverage
![](https://cdn-uat.mdedge.com/files/s3fs-public/styles/max_width_small/public/images/article_teasers/media_7170a26_Hepatitis_C_4.jpg)
High SVR achieved in decompensated HCV patients with 12-week therapy
The findings are encouraging because current treatment options for patients with HCV who have decompensated liver disease are limited, Dr....
Conference Coverage
![](https://cdn-uat.mdedge.com/files/s3fs-public/styles/max_width_small/public/images/article_teasers/media_acd78c8_Afdhal_Nezam_H_MA.jpg)
New direct-acting antivirals for HCV perform well in real world
Discontinuation rates for the new direct-acting antivirals are “not a major issue” in real world clinical practice.